

Dr Vishal Navani
Positions
Medical Oncologist
Arthur J.E. Child Comprehensive Cancer Centre
Member
Arnie Charbonneau Cancer Institute, Riddell Centre for Cancer Immunotherapy
Early Phase & Lung Cancer Clinical Trials Lead
Alberta Health Services
Affiliations
Clinical Assistant Professor
Cumming School of Medicine, Department of Oncology
Contact information
Phone number
Office: 587-231-5096
Location
Arthur Child Cancer Centre: Physicians Offices Level 10
For media enquiries, contact
Kelly Johnston
Senior Communications Specialist
Please submit your media request here
Preferred method of communication
Administrative Assistant
Yana Kada
Email: yana.kada@ahs.ca
Office: 587-231-5096
Background
Educational Background
Master of Arts Medical Sciences, University of Oxford,
Bachelor of Medicine Bachelor of Surgery Imperial College London,
Member of the Royal Colleges of Physicians UK Internal Medicine,
Fellow of the Royal Australasian College of Physicians Medical Oncology,
Biography
Dr. Vishal Navani is a Medical Oncologist at Arthur Child Cancer Centre, Calgary, Canada, and an Assistant Professor at the Cumming School of Medicine, University of Calgary, Calgary, Canada. He completed residency training in adult medical oncology & internal medicine, receiving fellowship of the Royal Australasian College of Physicians. He also holds Membership of the Royal College of Physicians (UK). Prior to his joint academic and clinical appointment in Calgary, he held a conjoint lectureship at the University of New South Wales, Sydney, Australia. He holds a Master of Arts (with honours) from the University of Oxford, UK and a Bachelor of Medicine & Bachelor of Surgery (with honours) from Imperial College London, UK.
In Calgary he leads the early phase & thoracic malignancy clinical trials divisions, sits on the data safety & monitoring committee and chairs the IIT funding committee. He is a member of the Canadian Drug Agency Clinical Expert Panel, providing expert input for HTA analysis of novel pharmaceutical submissions. Academically, he is the Director of Glans-Look Research, Canada’s largest thoracic malignancy real world evidence database. He has been PI on 8 trials & co-investigator on 18 trials across phases IA – III of the clinical development spectrum in thoracic & genitourinary malignancies & early phase clinical development. He currently leads Canada’s national recruitment in EVOLVE-LUNG-02, SGN-B6A & PACIFIC-8.
He has 82 published peer reviewed abstracts & manuscripts, with a H-Index of 13. He has received $1,300,000 in competitive grant funding. His work has been published in high profile journals such as the Lancet Oncology, Journal of Clinical Oncology & JAMA Oncology. He has authored 2 book chapters. He sits as an editorial review board member of Therapeutic Advances in Medical Oncology and peer reviewer for the JCO. He has won ASCO merit awards and authored pieces that have presented as Oral Presentations at the World Congress on Lung Cancer (Singapore 2024).
He sites on the national Canadian advisory boards for Janssen, AstraZeneca, BMS, Merck, Ipsen, Roche, Boehringer Ingelheim, Pfizer & Takeda, providing clinical development & medical affairs consultancy. He also provides clinical development advice & business development support to Novotech (CRO).
Research
Areas of Research
Participation in university strategic initiatives
Publications
In the News
- Lung Metastases, Cytoreductive Nephrectomy Use Associated With Responses to First-Line Immune-Oncology Combinations in mRCC.
- Several Studies Evaluate Agents in the First-Line, Second-Line, and Later Treatment of Advanced Kidney Cancer.
- ASCO GU 2022: Predictors of Objective Response to First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the IMDC.
- Clinically Meaningful Activity with Second Line Cabozantinib.
Are you the profile owner?
Login to edit.